Covina Arthritis - Research





	1	Inflammatory Arthritis Secondary to Metastatic Gastric Cancer

	2	Annual Slide Competition Winners (2003)

	3	Dieulafoy’s Lesion, a Rare Cause of Lower Gastrointestinal Hemorrhage

	4	Inverse association between circulating APRIL levels and serological and clinical disease activity in patients with systemic lupus erythematosus

	5	B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations

	6	Inliximab in the Treatment of AA Amyloidosis Secondary to Familial Mediterranean Fever [ACR - 2002]

	7	Infliximab as a Treatment of Familial Mediterranean Fever

	8	Cutaneous Reaction Patterns Associated with Infliximab Therapy. [ACR - 2003]

	9	New Treatment of CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME [EULAR - 2004]

	10	Hip Arthroplasty in a 101-Year-Old Patient

	11	SPINAL SUBARACHNOID HEMORRHAGE IN POLYARTERITIS NODOSA [EULAR - 2005]

	12	Rituximab treatment for resistant antiphospholipid syndrome

	13	Anakinra Prevents Symptoms of Familial Cold Autoinflammatory Syndrome and Raynaud's Disease

	14	MAINTENANCE ANAKINRA PREVENTS SYMPTOMS OF FAMILIAL COLD AUTOINFLAMMATORY SYNDROME AND RAYNAUD'S DISEASE [EULAR - 2006]

	15	Inflammatory Fibromyalgia: Is It Real? [ACR - 2007]

	16	Inflammatory Fibromyalgia: Is It Real? [EULAR - 2007]

	17	Use of Anti-TNF Agents in 15 Rheumatoid Arthritis Patients Undergoing Total Elbow Arthroplasty. [ACR - 2007]

	18	THE USE OF THE TNF ANTAGONIST INFLIXIMAB IN HEART TRANSPLANT RECIPIENTS: TWO CASE REPORTS [EULAR - 2007]

	19	ADALIMUMAB-INDUCED NONCASEATING GRANULOMA IN THE BONE MARROW OF A PATIENT BEING TREATED FOR RHEUMATOID ARTHRITIS [EULAR - 2007]

	20	USE OF ANTI-TNF AGENTS IN 15 RHEUMATOID ARTHRITIS PATIENTS UNDERGOING TOTAL ELBOW ARTHROPLASTY [EULAR - 2007]

	21	The use of the tumour necrosis factor antagonist infliximab in heart transplant recipients: two case reports.

	22	H Bassiouni, K Zaki, M Elshorbagi, A Mustapha, R Tantawi, H Ali, S Metyas, DG Arkfeld. Relating bone marrow oedema to hs-CRP in knee osteoarthritis. [Indian Journal of Rheumatology - 2010]

	23	Metyas SK, Tadros RM, Arkfeld DG. “Adalimumab-Induced Noncaseating Granuloma in the Bone Marrow of a Patient being Treated for Rheumatoid Arthritis.” [Rheumatol Int. 2008].

	24	Pregnancy in a patient with gouty arthritis secondary to pseudo-Bartter syndrome.



Clinical Trials: Principal Investigator:

	Protocol RA0055:
		A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination with Methotrexate for Inducing and Sustaining Clinical Response in the Treatment of DMARD-Naïve Adults with Early Active Rheumatoid Arthritis. October 2011 – Present. Sponsor: UCB
	Protocol WA25204:
		A Clinical Outcomes Study to Evaluate the Effects of IL-6 Receptor Blockade with Tocilizumab (TCZ) in Comparison with Etanercept (ETA) on the Rate of Cardiovascular Events in Patients with Moderate to Severe Rheumatoid Arthritis (RA). April 2011 – Present. Sponsor: Genentech
	Protocol TMX-67_301:
		A Multi-Center, Randomized, Active-Control, Phase 3B Study to Evaluate the Cardiovascular Safety of Febuxostat and Allopurinol in Subjects with Gout and Cardiovascular Comorbidities. Sponsor: Takeda Pharmaceuticals
	Protocol H9B-MC-BCDT:
		A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients with Systemic Lupus Erythematosus (SLE). Sponsor: Eli Lilly and Company
	Protocol RA0064:
		Phase 4, Randomized, 52-Week Study To Evaluate Two Assessment Tools To Predict Treatment Success At 52 Weeks Based On A Treatment Decision At Week 12 In Subjects With Moderate To Severe Rheumatoid Arthritis Receiving Cimzia. October 2010 – Present . Sponsor: UCB.
	Protocol I4V-MC-JADA :
		A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging, Parallel-Group, Phase 2b Study of LY3009104 in Patients With Active Rheumatoid Arthritis on Background Methotrexate Therapy. Sponsor: Eli Lilly and Company.
	Protocol RA0056:
		Randomized, Double-blind, Placebo-controlled, Dose Ranging Study With an Active Comparator to Evaluate the Efficacy and Safety of CDP6038 Administered Subcutaneously for 12 Weeks to Subjects With Rheumatoid Arthritis Having Previously Failed TNF-blocker Therapy. November 2010 – Present . Sponsor: UCB.
	Protocol ML22533:
		An Open Label, Randomized study to evaluate the safety, tolerability and efficacy of tocilizumab (TCZ) monotherapy or TCZ in combination with non-biologic DMARDs in patients with active rheumatoid arthritis who have an inadequate response to current non-biologic or biologic DMARDs. October 2009 – Present . Sponsor: Roche Pharmaceuticals.

	Protocol A4091043:
		A Multicenter, Randomized, Double-Blind, long term study of the safety of subcutaneous administration of Tanezumab in patients with Osteoarthritis of the Knee or Hip. Nov 2009 – Present. Sponsor: Pfizer, Inc.

	Protocol CNTO148 ART3002:
		A Golimumab Phase 3b, Multicenter, Switch assessment of Subcutaneous and Intravenous efficacy in Rheumatoid Arthritis Patients who have Inadequate disease control despite treatment. Sponsor : Centocor Inc

	Sunstone, U3839g:
		A long term study of the safety of Rituxan® in patients with Rheumatoid Arthritis after an inadequate response to previous anti TNF therapyJanuary 2007 till Present. Sponsor : Genentech, Inc. and Biogen Idec, Inc.